Data from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

MLA

Joan S. Brugge, et al. Data from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.c.6538137.v1.

APA

Joan S. Brugge, Gordon B. Mills, Deepak Sampath, Joel D. Leverson, Victor E. Velculescu, Dorothy Hallberg, Ursula A. Matulonis, Ronny Drapkin, Joyce F. Liu, Sangeetha Palakurthi, Laura M. Selfors, Ioannis K. Zervantonakis, & Claudia Iavarone. (2023). Data from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. https://doi.org/10.1158/1535-7163.c.6538137.v1

Chicago

Joan S. Brugge, Gordon B. Mills, Deepak Sampath, Joel D. Leverson, Victor E. Velculescu, Dorothy Hallberg, Ursula A. Matulonis, et al. 2023. “Data from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness,” April. doi:10.1158/1535-7163.c.6538137.v1.